India's Glenmark Pharma announces discovery of new monoclonal antibody

MUMBAI Mon Feb 4, 2013 4:31am EST

Related Topics

MUMBAI Feb 4 (Reuters) - Indian drugmaker Glenmark Pharmaceuticals said on Monday it has discovered a new molecule that can be used to treat diseases such as rheumatoid arthritis and inflammatory bowel disease.

The new molecule, named GBR 830, is an anti-OX40 monoclonal antibody, Glenmark said in a statement, adding that OX40 is responsible for some autoimmune diseases.

The company said it has initiated studies for an investigational new drug (IND) application to be filed with the U.S. Food and Drug Administration. (Reporting by Kaustubh Kulkarni in Mumbai; Editing by Jijo Jacob)

FILED UNDER:
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.